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Abstract
Background: Octamer-binding transcription factor 4A (OCT4A) is essential for cell pluripotency and reprogramming
both in humans and mice. To date, however, the function of human OCT4 in somatic and/or tumour tissues is
largely unknown.
Methods: RT-PCR was used to identify full-length splice forms of OCT4 transcripts in normal and cancer cells. A
FLAG-tagged OCT4 genomic transgene was used to identify OCT4-positive cancer cells. A potential role for OCT4 in
somatic cancer cells was examined by cell ablation of OCT4-positive cells using promoter-driven diphtheria toxin A.
OCT4 and secreted phosphoprotein 1 (SPP1) transcripts in early-stage lung adenocarcinoma tumours were analysed
and compared with pathohistological features.
Results: The results show that, unlike in murine cells, OCT4A and OCT4B variants are transcribed in both human
cancer cells and in adult tissues such as lung, kidney, uterus, breast, and eye. We found that OCT4A and SPP1C are
co-expressed in highly aggressive human breast, endometrial, and lung adenocarcinoma cell lines, but not in
mesothelial tumour cell lines. Ablation of OCT4-positive cells in lung adenocarcinoma cells significantly decreased
cell migration and SPP1C mRNA levels. The OCT4A/SPP1C axis was found in primary, early-stage, lung
adenocarcinoma tumours.
Conclusions: Co-expression of OCT4 and SPP1 may correlate with cancer aggressiveness, and the OCT4A/SPP1C axis
may help identify early-stage high-risk patients with lung adenocarcinoma. Contrary to the case in mice, our data
strongly suggest a critical role for OCT4A and SPP1C in the development and progression of human epithelial cancers.
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Background
Cancer stem cells (CSCs) or tumour-initiating cells
(TICs) [1, 2] are essential for understanding drug resist-
ance, tumour relapse, metastasis, and tumour cell behav-
iour in clinical treatments. Single-cell mRNA sequencing
is a powerful technology for understanding cellular het-
erogeneity in normal and tumour tissues and has
enhanced our understanding of rare cells that might affect
drug resistance and relapse in cancer treatment; however,
this method has not yet been optimised for the detection
of genes expressed at low levels, such as transcription
factors [3, 4].
The POU class 5 homeobox 1 (POU5F1)/octamer-bind-
ing transcription factor 4A (OCT4) gene encoding the
octamer-binding transcription factor (also known as
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OCT3A and OCT3/4A) is particularly crucial for cell pluri-
potency in early embryonic development and propagation
of the mammalian germline [5–9]. Further, it is a marker
for germ-cell tumours and a potential CSCs marker [6, 10].
OCT4 is known to be involved in the translocation with the
Ewing’s sarcoma gene on chromosome 21, leading to
tumorigenesis in humans [11, 12]. Another study reported
the identification of CSC-like phenotype by OCT4 pro-
moter mediated activity in an osteosarcoma cell line [13].
Although these studies suggest that OCT4 plays an role in
human somatic cancers, its somatic function is controver-
sial. Since its proposed role is based on the results derived
from multiple transcript variants and related, active pseudo-
genes, this may have introduced false positives and led to
an erroneous or questionable interpretation of the data
[14–16]. In addition, previous studies also indicated that
OCT4A does not play a functional role in adult somatic
murine tissues [17, 18], therefore, many researchers have
been reticent to accept a role for OCT4A in human adult
somatic tissues or related cancers [14, 18–22].
In our previous study, we developed a highly specific
reverse transcription polymerase chain reaction (RT-
PCR) assay to analyse the human OCT4 gene, which
eliminated false positives and identified multiple tran-
scripts in human carcinoma cell lines [16]. Additionally,
we reported that OCT4 was translated in a subpopula-
tion of human endometrial cancer cells characterised by
enhanced cell migration and invasion [16]. Consistent
with our findings, another group reported that endogen-
ous OCT4A functions as a transcription factor in som-
atic cancer cells [23]. These results renew the discussion
surrounding a critical role for OCT4A or other OCT4
variants in human somatic cancers and germ-cell tu-
mours. To our knowledge, variant-specific expression of
OCT4 transcripts could not be assessed using currently
available high-throughput databases [18, 24]; therefore,
in the present study, we explored the potential of mul-
tiple OCT4 transcript variants to act as prognostic bio-
markers in human somatic cancers.
Secreted phosphoprotein 1 (SPP1) [also designated as
osteopontin (OPN) [25, 26]] mediates critical processes
involved in cancer progression, including immune re-
sponse, cell adhesion and migration, and tumourigenesis
[27–29]. Three major SPP1-transcript splice variants
exist that encode SPP1A (the full-length isoform), SPP1B
(lacking exon 5), and SPP1C (lacking exon 4). Each SPP1
isoform is characterised as a potential prognostic marker
for multiple malignancies, such as lung, breast, and ovarian
cancers [28]; however, they cannot be used as universal
markers for cancer prognosis based on the variance in their
expression and associated signalling among tissues [30].
We hypothesised that various OCT4- and SPP1-transcript
variants might be associated with the development and ag-
gressiveness of various human somatic cancers; therefore,
we comprehensively assessed the expression of these vari-
ants in healthy and cancerous human tissues in order to
characterise their potential biological and clinical roles in
human lung adenocarcinoma (LUAD), which is the leading
cause of cancer-related deaths worldwide [31].
Methods
Cell culture
Lung cancer cell lines (HCC827, HCC827GRH2,
HCC827ARH, H1299, PC-9, HCC4006, and H1975),
mesothelioma cell lines (MSTO-211H and H2052), and
immortalised cell lines (HBEC-5KT and MeT-5A) were
provided and described by the co-authors [32]. Other
cell lines were obtained from Japanese Collection of
Research Bioresources (JCRB, Osaka, Japan), American
Type Culture Collection (ATCC, Manassas, VA) and
European Collection of Authenticated Cell Cultures
(ECACC, Salisbury, UK). MCF7 (JCRB0134), HEC50B
(JCRB1145), MDAMB231 (ATCC HTB-26™), PA-1
(ATCC CRL-1572™) and Ishikawa (ECACC99040201)
were purchased in 2017 or later and used in this study.
All cell types are summarized in supplementary infor-
mation (Table S1). RNA extraction from these cell lines
was performed within 2 weeks from receipt and not ex-
ceeding 3 passages. Cells for bioassay were for myco-
plasma contamination and passaged for < 6 months
prior to experimentation. For monolayer culture, cells
were maintained in culture dishes or plates (Sumitomo
Bakelite Co. Ltd., Shinagawa, Japan) in Dulbecco’s
modified Eagle medium (DMEM) supplemented with
8% foetal bovine serum. Sphere-formation assays were
performed as previously described [32]. Briefly, a total
of 5 × 10 [3] single, dissociated cells were prepared per
24-well plate with an ultra-low attachment surface
(Corning, Corning, NY, USA) and incubated for 14 days
in DMEM/F12 medium supplemented with B29 supple-
ment (Thermo Fisher Scientific, Waltham, MA, USA),
epidermal growth factor (20 ng/mL; PeproTech, Rocky
Hill, NJ, USA), and fibroblast growth factor 2 (10 ng/
mL; PeproTech). The number of spheres > 150 μm in
diameter was microscopically counted per well.
Experimental animals and ethics statement
C57BL/6 N mice (4-months and 3-days old) were ob-
tained from Japan SLC Co. (Shizuoka, Japan) and housed
in rooms maintained at constant temperature and
humidity with a 12 h light/dark cycle. For this study, tis-
sues were obtained from mice that had to be killed
owing to excessive breeding. This study was approved by
the Animal Care and Use Committee of RIKEN and
Okayama University and performed in accordance with
the Japanese Council on Animal Care guidelines (No.
AH15–09-5, No. OKU-2012259). All animal procedures
were performed in accordance with approved protocols.
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Total RNA extraction and cDNA preparation
Total RNA samples from normal human tissues (Table S2)
were purchased from Agilent Technologies (BioChain;
Santa Clara, CA, USA), Clontech (Takara, Shiga, Japan),
and Zyagen (San Diego, CA, USA). Clinical tumour tissues
were stored in RNAlater stabilisation solution (Thermo
Fisher Scientific). We used the total RNA samples from 3-
days old mice, which we had analysed before [18]. Total
RNA from fresh tissues was extracted using ISOGENE II
(Nippon Gene Co. Ltd., Toyama, Japan) and immediately
homogenised (Beads Crusher μT-12; TAITEC, Saitama,
Japan) and processed according to the manufacturer’s
instructions.
RT-PCR
cDNA was synthesised from 0.5 μg RNA using oligo-dT
primers and a PrimeScript II first-strand cDNA synthesis
kit (#6210A/B; Takara) according to the manufacturer’s
instructions. Reverse transcriptase negative controls
were used to assess genomic DNA contamination. The
primers used for PCR are described in Table S3 [16].
We used two PCR enzymes [EmeraldAmp PCR Master
Mix, RR300A; Takara) or PrimeSTAR HS DNA poly-
merase (R010A; Takara)] in a total volume of 20 μL.
Thermal cycling conditions for OCT4 were; 35 cycles at
96 °C for 30 s and 68 °C for 2 min. Those for SPP1 were
30 cycles at 96 °C for 30 s and 68 °C for 1 min. The PCR
products (~ 20%) were separated on a 1.5% agarose gel,
stained with ethidium bromide, and visualised under
ultraviolet light (312-nm wavelength). Images were cap-
tured using a GelPrint 2000i system (Genomic Solutions,
Ann Arbor, MI, USA).
Cloning and sequencing analysis
After electrophoretic separation, PCR amplicons were
extracted using the QIAquick gel extraction kit (#28706;
Qiagen, Hilden, Germany) and cloned into the pCR-Blunt
vector (#K280040; Life Technologies, Carlsbad, CA, USA).
Isolated plasmids were analysed on an ABI3130 sequencer
(Central Research Laboratory, Okayama University Medical
School, Okayama, Japan) using M13 forward and reverse
primers. Plasmids extracted from randomly selected col-
onies were classified based on their sequences, which were
analysed using BLAST (https://blast.ncbi.nlm.nih.gov/Blast.
cgi) or a genetic information processing software (Genetyx
Corporation, Tokyo, Japan).
Wound-healing assay
Wound-healing migration assays were performed ac-
cording to the manufacturer’s instructions (#80209; Ibidi
GmbH, Martinsried, Planegg, Germany). Transfected
cells (2.5 × 104) were seeded into each well, and the cul-
ture insert was gently removed after 24 h. Images were
captured over time post-wounding, and the wound area
was calculated using ImageJ software (NIH, Bethesda,
MD, USA).
Plasmid construction and transfection
Plasmids were constructed as previously described [16].
Briefly, a POU5F1 genomic DNA fragment (− 5000 to +
10,784 bp) was subcloned from BAC clone RPCI-11-
1058 J10 using a BAC subcloning kit (Gene Bridges,
Heidelberg, Germany) to create pOCT4Gen. An in-
frame FLAG tag was added to the 3′ end of the exon 5
open reading frame to generate pOCT4Gen-FLAG. The
backbone of this vector contained a CMV promoter-
driven red fluorescent protein (RFP) for visualisation of
the transfected cells. A NcoI fragment of pOCT4Gen (−
4733 to + 77 bp) was ligated into the NcoI site of the
diphtheria toxin fragment A (DT-A) vector and an en-
hanced GFP (EGFP) vector to construct pOCT4-DTA
and pOCT4-GFP, respectively. Plasmid DNA transfec-
tion was performed using Lipofectamine 2000 or 3000
(Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Cells were transfected with
pOCT4-GFP or pOCT4-DTA and incubated for 24 h to
assess the biological effects of OCT4-positive cell abla-
tion. The same number of viable cells was used for each
assay. The study was conducted in accordance with
Okayama University Safety Committee for Recombinant
DNA Experiments guidelines.
Immunocytochemistry
Non-transfected or transfected cells were fixed in 4%
paraformaldehyde for 15 min at 25 °C and permeabilised
in 0·2% Triton X-100 for 20 min. Cells were incubated
with mouse monoclonal anti-FLAG antibodies (#F1804;
Sigma-Aldrich, St. Louis, MO, USA) at 25 °C for 45 min,
washed thrice in phosphate-buffered saline (PBS), incu-
bated with secondary antibodies (Alexa 488-conjugated
goat anti-mouse IgG; #ab150113; Invitrogen, Carlsbad,
CA, USA), and washed thrice in PBS. The cells were
then counterstained with 4′,6-diamidino-2-phenylindole
(#D1306; Thermo Fisher Scientific) and visualised under a
fluorescence microscope (Zeiss Axiovert135, Germany).
PBS was used instead of the primary antibody in negative
controls.
Transwell migration assay
Cell migration assays were performed using 24-well cell
culture inserts with 8-μm pores (#354480; Corning).
Transfected cells (2.5 × 104) were seeded into the top
chambers of the inserts, and normal growth medium
was added to the lower chambers. After 24 h, cells
remaining in the upper chamber were removed, and
those attached to the underside of the membrane in the
lower chamber were fixed with methanol, stained with
10% Giemsa solution (#15003; Muto Pure Chemicals,
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Tokyo, Japan), and counted under a light microscope.
Five representative fields per well and three replicate
wells per condition were analysed.
Real-time quantitative PCR (qPCR) for SPP1C
cDNA was synthesised from 0.5 μg RNA using random
decamer primers for qPCR analysis. Gene expression
analysis was carried out utilizing KAPA SYBR FAST
Universal 2× qPCR Master Mix (Kapa Biosystems, Bos-
ton, USA) on a Step One Plus real time PCR system
(Thermo Fisher Scientific) according to the manufac-
turer’s protocol. PCR amplification conditions were:
95 °C for 2 min, followed by 40 cycles of 95 °C for 5 s and
60 °C for 30 s, and melting-curve analysis (60–95 °C with
a heating rate of 0.3 °C/s and continuous fluorescence
measurement). Relative gene expression of SPP1C was
evaluated using the ΔΔCt method and normalisation to
18S ribosomal RNA or beta-actin. Sequences of these
PCR primer sets were described in Table S3.
Analysis of clinical tissue samples
All LUAD patients were stage I at the time of diagnosis.
Tumour tissues were collected during surgical resections
(2010–2016) and snap-frozen at − 80 °C or stored in
RNAlater solution (Qiagen) until RNA extraction. LUAD
patient samples (77 cases) were collected from Okayama
University Hospital, and high-quality RNA was extracted
from 58 tumour specimens. Clinicopathological data for
each patient were obtained retrospectively from the
medical records of Okayama University Hospital Bio-
bank (Okadai Biobank; Ref. No. OC17003), and histo-
pathologic review of tumour specimens was conducted
at Okayama University Hospital. Clinical and histo-
pathological characteristics are described in Table S5.
This study (No. K1612–023) was approved by the ethical
committee of the Okayama University Graduate School
of Medicine, Dentistry, and Pharmaceutical Sciences,
(Okayama, Japan).
Statistics
Data represent the mean ± standard deviation (SD) of at
least three independent experiments. Statistical evaluation
was conducted by paired, two-tailed Student’s t-test and cor-
relations between OCT4A and SPP1C expression in LUAD
tumours were analysed using Fisher’s exact test. Differences
with P < 0.05 were considered statistically significant.
Results
OCT4-transcript variants are expressed in human somatic
tissues at lower levels than in PA-1, a human ovarian
teratocarcinoma cell line
We examined the expression of OCT4-transcript variants
in 24 commercially available RNA samples from human
tissues and cells using highly specific primer sets [16]
(Table S3). Consistent with our previous findings [16], the
PCR and sequencing analysis revealed that the primer sets
specifically amplified the desired target cDNA; however,
faint bands for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) in thyroid and breast samples indicated minor
genomic DNA contamination (Fig. 1a).
Unexpectedly, OCT4A and OCT4B variant transcripts
were readily detected in testis, ovary, and 13 other somatic
tissues (eye, pancreas, uterus, lung, breast, kidney, placenta,
prostate, small intestine, spinal cord, stomach, colon, and
liver) (Fig. 1a). A schematic diagram of human OCT4A-
and OCT4B-transcript variant structures and the size of the
expected PCR products are displayed in Fig. 1b [16]. Se-
quencing analysis of the PCR products revealed that they
were derived from human OCT4A and OCT4A1, as well as
from at least four different human OCT4B-transcript vari-
ants (OCT4B, OCT4B1, OCT4B2, and OCT4Bns) (Table
S4). OCT4A1, a minor transcript variant, has a 118-bp in-
sertion in exon 1C and located between 3569- and 3687-bp
downstream of the exon 1/intron 1 boundary, which en-
codes an in-frame endogenous TGA stop codon, as de-
scribed previously [16]. Therefore, we focused only on
OCT4A, the full-length form of the variants, in this study.
Only OCT4B variants were readily detectable in the thy-
roid, peripheral leukocytes, cerebellum, heart, skeletal
muscle, and two kinds of mesenchymal stem cells derived
from the adipose tissue (MSC-AT) or bone marrow tissue
(MSC-BM) (Fig. 1a). In peripheral leukocytes, bone marrow,
and spleen, neither OCT4A nor OCT4B variants were de-
tectable (Fig. 1a), suggesting that OCT4-transcript variants
are differentially expressed in adult human somatic tissues.
Next, we sought to examine whether OCT4-transcript
variants were ubiquitously or selectively expressed in
certain individuals. Using commercially available total
RNA isolated from the lungs of two separate donors, we
found that the same OCT4A- and OCT4B-transcript var-
iants were expressed in the lungs of both individuals
(Fig. 1c). The RNA samples isolated from the eye, thy-
roid, pancreas, kidney, skeletal muscle, and stomach
(Fig. 1a) were also from a single donor, and all of these
samples expressed OCT4B, whereas except for the skel-
etal muscle sample, all others expressed OCT4A. Col-
lectively, these results indicated that OCT4 expression
does not exhibit person-to-person variation and is ubi-
quitously expressed in certain human somatic tissues.
Notably, OCT4A-expression levels in the liver, lung,
and pancreas were similar to or higher than those in the
testis (Fig. 1a). Therefore, we further examined OCT4A-
expression levels in these tissues by semi-quantitative
RT-PCR. Comparison of the band intensities of the PCR
products with serial dilutions of cDNA derived from
RNA isolated from PA-1 cells (Fig. 1d) revealed that
band intensities associated with OCT4A in the adult tis-
sues were 1/1000- to 1/10000-times lower than OCT4A
Koshimune et al. BMC Cancer          (2020) 20:521 Page 4 of 13
in PA-1 cells. This might indicate that OCT4A tran-
scripts are highly expressed by a small subpopulation of
cells in certain adult somatic tissues, where their expres-
sion might be functionally significant.
Oct4-transcript variants are not expressed in adult murine
somatic tissues
To date, no functional roles for OCT4A in murine, som-
atic, normal, or tumour tissues have been substantiated
[17, 18]. In a previous report, we found no Oct4A-tran-
script variants but instead identified novel transcript var-
iants (Oct4B and Oct4C) in postnatal murine tissues
[18]. Based on the OCT4 expression observed in human
somatic tissues (Fig. 1), we re-examined the expression
of Oct4-transcript variants in 4-month-old (adult) mouse
tissues using a previously [18] and newly developed PCR
primer set (Table S3). It was confirmed that Oct4A and
Oct4B variants are expressed in testis but not in adult
Fig. 1 OCT4A- and OCT4B-transcript variants are expressed in various human somatic tissues. a Gel electrophoresis of PCR products derived from primer
sets specific for human OCT4A- and OCT4B-transcript variants and GAPDH (loading control). RT+ and RT− indicate treatments with and without treatment
of reverse transcriptase, respectively. Detailed information on RNA sources is presented in Table S2. Three independent experiments were performed, and
representative images are shown. Arrow, OCT4A; arrowhead: OCT4Bns; bracket: OCT4Bv (B-splice variants other than OCT4Bns). b The size and position of
expected bands are indicated in a partially expanded image surrounded by a dashed line (left). Schematic diagram of human OCT4 mRNA variant
structures (right). c Expression of human OCT4A- and OCT4B-transcript variants in the pooled sample and in two samples of normal adult lung tissues from
different sources. d Semi-quantitative comparison of human OCT4A-expression levels between PA-1 cells and adult tissues (liver, lung, pancreas, and testis).
A 10-fold series of dilutions of cDNA from PA-1 cells were used for standard PCR, and a 2-fold series of dilutions of cDNA from human tissue samples were
used for comparison of PCR samples. All full-length gels are presented in Supplementary Figs. S4–1-4
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murine somatic tissues (Fig. S1). This clear difference in
the expression of OCT4/Oct4 transcripts in human and
murine somatic tissues reveals the potential inadequacy
of using a mouse model to characterise the somatic
function of human OCT4.
Expression of OCT4-transcript variants in malignant and
non-malignant cells of human somatic tissues
In a prior analysis [16], we found that only OCT4Bns (a
no-splice form of the OCT4B transcript) was expressed
in normal human tissue-derived cell lines and certain
cancer cells. The function of OCT4Bns remains un-
known, but its expression does not appear to correlate
with the expression of other splice variants (OCT4A
and/or OCT4Bv). Moreover, we reported that multiple
OCT4A and OCT4Bv transcripts were readily detected
in A549, an aggressive human lung cancer line, and in
HEC50B, an aggressive endometrial cancer cell line;
however, only a few transcript variants were detected in
Ishikawa cells, a non-aggressive endometrial cancer cell
line [16]. In the present study, to confirm a potential
role for OCT4A and OCT4Bv (B-splice variants save for
OCT4Bns) in the aggressiveness of human somatic can-
cers, we examined the expression of OCT4 transcripts in
breast and various lung tumour cell lines (Fig. 2b and c).
We observed that the predicted OCT4A and OCT4Bv
PCR products were readily detected in MDA-MB-231, a
highly aggressive breast cancer cell line (Fig. 2b). Con-
versely, consistent with our previous data, OCT4A and
OCT4Bv transcripts were undetectable or expressed at
very low levels in MCF7, a non-aggressive cancer cell
line (Fig. 2b) [16], suggesting that the expression of these
OCT4 transcripts is positively correlated with the aggres-
siveness of breast and endometrial cancer cells, which is
inconsistent with a previous bioinformatics analysis [24].
Similarly, in highly aggressive lung cancer cell lines
(HCC827 GRH2, HCC827 ARH, and PC9), as well as
A549, we clearly detected OCT4A and OCT4Bv tran-
scripts (Fig. 2c), whereas their transcripts were undetect-
able in less aggressive cancer cell lines (HCC827 and
H1975). Moreover, in a non-aggressive lung cancer line
(HCC4006) and an immortalised bronchial epithelial cell
line (HEBC-5KT), we detected OCT4Bv but not OCT4A
transcripts. Notably, OCT4A and OCT4Bv transcripts
were not detected in mesothelial tumour cell lines
(MSTO-211H and H2052), a non-malignant mesothelial
cell line (Met-5A), or an aggressive large-cell lung cancer
line (H1299) that is p53-null [31]. The absence of
OCT4-transcript expression (except for the OCT4Bns
variant) in these cell lines might result from lung cancer
cells being of different origins. Alternatively, all analysed
cell lines highly expressing OCT4A and OCT4Bv transcripts
represent cancers of epithelial origin (Table S1). Based on
these data, we hypothesised that OCT4 splicing variants
might be involved in the progression of certain epithelial
cancers, including lung, uterus, and breast cancers.
A possible role for OCT4 in cancer cell migration
Collective migration is a hallmark of cancer cell invasion
and metastasis [33, 34]. Wound-healing assays revealed
that MDA-MD-231 and HEC50B cells migrated faster
than MCF7 and Ishikawa cells, respectively (Fig. 2d)
[35]. We herein focused on the effect of OCT4 on the
migration of aggressive A549 LUAD cells, because we
previously reported a small subpopulation of OCT4-
positive cells in A549 cells [16]. To assess the potential
effect of OCT4 on collective migration, we evaluated the
effects of DTA-mediated ablation of A549 cells. We
transfected cells with plasmids using the OCT4 pro-
moter to express either DTA (pOCT4-DTA) or GFP
(pOCT4-GFP) [16] and confirmed that cellular morph-
ology and cell numbers were not significantly affected by
transfection with either plasmid (Fig. 2e, left). We observed
a significant difference in the migration of A549 cells trans-
fected with pOCT4-DTA compared with those transfected
with the control plasmid (pOCT4-GFP) (Fig. 2e). These
data suggested a significant contribution of OCT4 to the
migration and aggressiveness of A549 LUAD cells.
OCT4- and SPP1-transcript variant expression is
correlated in human cancer cell lines
SPP1 is a multifunctional cytokine that affects cell prolif-
eration, survival, drug resistance, invasion, and stem-like
behaviour and promotes the invasion and metastatic pro-
gression of many carcinomas [27–29]. Based on these ef-
fects, we proffered that there may be a possible association
between the expression of OCT4 and SPP1 variants in
cancer cells. We found significant expression of SPP1,
OCT4A, and OCT4Bv transcripts in MDA-MB-231,
HEC50B, and A549 (cancer cell lines) and in HCC827
GRH2 and HCC827 ARH (drug-resistant lung cancer cell
lines) (Fig. 2b and c). Interestingly, we observed a signifi-
cant correlation between OCT4A and SPP1C expression
in the aggressive cancer cell lines (Fig. 2b and c). Notably,
OCT4A and SPP1C were expressed at much lower levels
in the parental cell line (HCC827) compared with the two
drug-resistant cell lines (HCC827 GRH2 and HCC827
ARH) (Fig. 2c). Furthermore, very few (if any) OCT4A and
SPP1C transcripts were detected in non-aggressive cancer
lines (MCF7 and Ishikawa) (Fig. 2b). Like previous studies
on the breast and ovary [35–37], SPP1C was not detected
in adult normal lung tissues, although other SPP1 variants
were expressed (Fig. 2a). However, we confirmed the ex-
pression of SPP1C in several kinds of human adult non-
tumour tissues (Fig. S2), supporting the idea that SPP1C
alone cannot serve as a selective marker for cancer diag-
nosis [31]. Our results raise a new possibility that the
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OCT4A/SPP1C axis might closely relate to aggressiveness
in certain human epithelial cancers.
Characterisation of OCT4-positive cells in HCC827 and
HCC827 GRH2 LUAD cell lines
HCC827 GRH2 is a gefitinib-resistant cell line derived
from HCC827 LUAD cells [32] and it exhibits stem cell-
like properties [32]. Previous cDNA microarray analysis
showed that ALDH1A and SPP1 expression accounts for
the highest increase in HCC827 GRH2 cells relative to
the parental cell line [32]. Alternatively, OCT4 expres-
sion was not detected in the microarray data, suggesting
that this analysis may be unsuitable for the detection of
specific OCT4A-transcript variants in cancer cells [16].
Our highly specific method identified OCT4A, OCT4Bv,
and SPP1 transcripts in HCC827 GRH2 cells but not in
parental HCC827 cells (Fig. 2c).
We herein examined collective migration activity in
HCC827 GRH2 cells compared with the parental
HCC827 cells. The migration of HCC827 GRH2 cells,
Fig. 2 OCT4 and SPP1 expression in human various cell lines and OCT4 in cell migration. Gel electrophoresis of PCR products using primer sets specific
to human OCT4A, OCT4Bv, SPP1-all, SPP1C, and GAPDH (positive controls). RT-PCR using specific primer sets for detecting OCT4A and OCT4B variants
and SPP1 variants, respectively (Table S3). RT+ and RT− indicate treatments with and without reverse transcriptase, respectively. Arrowheads, OCT4Bns
bands; and asterisks, OCT4B-splice variants (OCT4B, OCT4B1, and OCT4B2; denoted as OCT4Bv). a Pooled RNA samples from two patients and human
lung tissues (Table S2). b–d Representative bright-field images of wound-healing experiments using endometrial and breast cancer cell lines (Ishikawa
vs HEC50B; and MCF7 vs MDA-MD-231) acquired at 24- and 48-h post-wounding. Scale bar: 100 μm. e Representative bright-field images of A549 cells
transfected with pOCT4-DTA or pOCT4-GFP control plasmids and acquired at 12-h post-wounding. The migration rate is expressed as the percentage
of wound-closure area. Data represent the mean ± standard deviation of the closure area at each time point from three independent experiments.
*P < 0.05compared with the control. Scale bar: 100 μm. All full-length gels are presented in Supplementary Figs. S5–1-5
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which express both OCT4 and SPP1 transcripts, was
much higher than that of parental HCC827 cells (Fig. 3a
and b). We then identified OCT4-positive cells using an
OCT4-FLAG-tagged genomic transgene (pOCT4-Gen-
FLAG) [16] containing CMV-RFP sequences to visualise
transfected cells (illustrated in Fig. 3c). The ratio of cells
that were stained for the FLAG antibody to those ex-
pressing RFP was higher in HCC827 GRH2 cells (53/
800; 6·6%) than in parental HCC827 cells (1/184; < 0.5%)
(Fig. 3c), indicating a higher percentage of OCT4-
positive cells in HCC827 GRH2 cells relative to HCC827
cells, which is consistent with the endogenous transcript
levels (Fig. 2c).
To clarify the role of OCT4-positive cancer cells in the
highly aggressive HCC827 GRH2 cell line, we evaluated
the effects of DTA-mediated ablation. We transfected
the cells with either pOCT4-DTA or pOCT4-GFP (Fig.
3d) and observed that the cellular morphology was not
significantly altered by pOCT4-DTA (Fig. 3d); however,
the percentage of OCT4-positive cells dropped from 5.9
to 1.1% (Fig. 3e). Moreover, sphere-formation was not
significantly affected by ablating OCT4-positive cells
from the HCC827 GRH2 culture (Fig. 3f), but the migra-
tion significantly decreased (Fig. 3g). These data indi-
cated that the OCT4-positive subpopulation might
enhance HCC827 GRH2 cell migration, similar to its ef-
fect on the poorly differentiated endometrial cancer cell
line HEC50B [16]. Furthermore, ablating OCT4-positive
cells caused a significant decrease in SPP1C mRNA
levels (Fig. 3h), suggesting that OCT4 and SPP1C might
be expressed by the same cancer cells. These data
strongly suggested that the OCT4/SPP1 axis might en-
hance the aggressiveness of somatic cancers. Therefore,
we evaluated the potential significance of OCT4- and
SPP1-transcript variants in human clinical tumour
tissues.
The OCT4/SPP1 axis in early-stage LUAD patients
LUAD is the most common subtype of lung cancer,
which is a major global health threat owing to its high
disease-associated mortality rates [31]. To examine
whether the OCT4/SPP1 axis can help identify patients
with early-stage LUAD at high-risk of metastasis, we in-
vestigated primary tumours of early-stage (Stage I)
LUAD patients (Table S5), which were collected from
surgical patients at Okayama University. Using the RT-
PCR method described above, we identified the OCT4-
and SPP1-transcript variants expressed in primary
tumour samples of 58 patients and compared them with
the histological grade and tissue-specific invasion data
(Fig. 4 and Fig. S3; Table S5). We separated expression
levels into two or three categories. OCT4A and OCT4Bv:
high, easily detectable; low, faintly detectable; and minus,
undetectable. SPP1-all: detectable (d) or undetectable
(ud). SPP1C: clear bands, reproducibly detectable (d); or
very few or no bands, undetectable (ud) (Fig. S3).
OCT4Bv was detected in 49 of the 58 clinical tumour
samples, 42 of these also expressing OCT4A transcripts
(Fig. 4a and Table S5). These results suggest that
OCT4A and OCT4Bv might play a significant role in the
development and progression of human LUAD. Within
individual tumours, OCT4A-expression levels might cor-
relate with the number of OCT4-positive cells, which
are characterised by enhanced migration in lung cancer
cell lines (Fig. 2e and Fig. 3g). All tumour samples ex-
pressing OCT4A at high levels also expressed high levels
of OCT4Bv (24/24; Table S5). Assessing accurate
OCT4A expression levels in tumour tissues might help
diagnose LUAD. Alternatively, SPP1 transcripts were de-
tected in multiple tumour samples (42/58) (Fig. 4a), con-
sistent with previous reports [38, 39]. However, SPP1C
transcript variants were detected in < 50% the samples
(26/58; Fig. 4a and Table S5), suggesting that SPP1C ex-
pression might be a potential diagnostic and prognostic
marker for early-stage LUAD, which is consistent with
previous studies of breast and ovarian cancers [37, 40].
However, we found that all tumours expressing SPP1C
also expressed SPP1A and/or SPP1B (Table S5); there-
fore, our data do not refute a potential role for SPP1A
and/or SPP1B isoforms in LUAD tumours. Nevertheless,
SPP1C expression, which closely correlates with the
overexpression of full-length SPP1, might represent a
diagnostic marker for early-stage LUAD.
Histopathological assessment is indispensable for ac-
curate diagnosis of lung cancer. Local vascular invasion
is closely associated with an increased risk of future me-
tastasis and death after surgery for early-stage NSCLC
[41]; therefore, we examined the potential relationship
between the OCT4A/SPP1C axis and local micro inva-
sion in early-stage LUAD tumours (Fig. 4a). The lymph-
atic invasion was found in nine patients. Of these nine
tumours, OCT4A was detected in eight, and SPP1C was
detected in four. Similarly, vascular invasion was found
in seven patients. Of these, all seven tumours expressed
OCT4A, and five expressed SPP1C. Pleural invasion was
found in six patients, all of which expressed OCT4A,
and five expressed SPP1C. In patients with histopatho-
logical local invasion (score 1–3), OCT4A and/or SPP1C
expression was detected in most tumours (16/17; 94%),
OCT4A and SPP1C co-expression was detected in 10/17
cases (59%), only OCT4A expression in 5/17 cases (29%),
and no tumours expressed only SPP1C (0/17; 0%). To
evaluate the relationship between the OCT4/SPP1C axis
and the presence of local invasion, we scored and com-
pared the results (Fig. 4b and c). Remarkably, almost no
cases showed local invasion in which the tumours
expressed no OCT4 or SPP1 transcripts (gene score: 0;
1/9). Alternatively, in the six tumours lacking micro
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Fig. 3 (See legend on next page.)
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invasion, categorised as a subtype of adenocarcinoma in
situ (Fig. 4b, blue numbers), a range of OCT4 and SPP1
gene scores were observed. Similarly, in cases with no
available pathohistological observations, the gene scores
were variable (Fig. 4b, pathohistological score: 0). Fur-
ther investigation on the outcomes of these patients will
clarify whether the OCT4A/SPP1C axis could reflect
postoperative prognoses for patients without any patho-
histological risk.
Notably, the tumours of all three patients who relapsed
or had distant metastases during our observation period
belonged to the group with the highest gene score [Figs. 4b
and d; and Table S5 (case numbers 16, 59, and 62)]. Among
these patients, one (No. 16) had been diagnosed with no
(See figure on previous page.)
Fig. 3 Characterisation of the OCT4-positive cell population in HCC827 and HCC827 GRH2 cells. a Representative bright-field images of wound-
healing experiments acquired at 0- and 12-h post-wounding. Scale bar: 100 μm. b Migration rate was expressed as the percentage of wound-
closure area. c Detection of possible OCT4 translation in HCC827 and HCC827 GRH2 cells using the FLAG-tagged genomic transgene (pOCT4Gen-
FLAG) according to immunocytochemistry. RED: transfected RFP-positive cells; GREEN: FLAG-positive cells. The ratio of FLAG−/RFP-positive cells for
each is indicated. Scale bar: 100 μm. d–h Effects of ablating OCT4-positive cells from HCC827 GRH2 cells. d Phase-contrast image of pOCT4-EGFP-
or pOCT4-DTA-transfected HCC827 GRH2 cells at 24-h post-transfection. These cells were used for the assays described in e–h. e OCT4-positive
cell rate among pOCT4-DTA-transfected HCC827 GRH2 cells. f Sphere-formation activities, g cell migration according to Transwell migration
assays, and h SPP1C mRNA levels by qPCR. Data represent the mean ± standard deviation from three independent experiments. *P < 0.05, **P <
0.005, ***P < 0.0005, compared with the control. Scale bar: 100 μm
Fig. 4 The OCT4/SPP1 axis in early-stage LUAD. a Summary of pathohistological factors, as well as OCT4- and SPP1-transcript expression in
tumours from 58 LUAD patients. Values represent the number of patients harbouring tumours with designated characteristics. b Relationship between
gene expression in the OCT4A/SPP1 axis and pathohistological scores. OCT4A scores: not detected (0), low levels (1), and high levels (2); SPP1 scores:
not detected (0), SPP1-all detected (0.5), and both SPP1-all and SPP1C detected (1). Gene scores represent the total scores of OCT4A and SPP1. Criteria
for evaluation of their expression levels was shown in Fig. S3. The pathohistological score is indicated as a total of each pathological score: Lymphatic
invasion (Ly) (+): 1; vascular (Ve) (+): 1; and pleural invasion (pl) (+): 1. Blue numbers indicate cases of adenocarcinoma in situ, and red numbers
indicate relapse cases. c Correlation between OCT4A and SPP1C expression in tumour tissues. The X-axis indicates SPP1C-expression levels (detected or
undetected), and the Y-axis indicates OCT4A-expression levels (high and low levels or undetected). d Scatter plot showing the relationship between
gene expression related to the OCT4A/SPP1 axis and levels of pathohistological risk. Each scatter point is represented by the following: an X-
coordinate for OCT4A-expression levels (−: undetected; Low: detected at low levels; and High: detected at high levels), a Y-coordinate for SPP1-all and/
or SPP1C expression (−: undetected; a: detection of SPP1-all detected; a + c: detection of SPP1-all and SPP1C); plot size: case number (each number
indicates the number of cases); and colour [each colour represents pathohistological risk (blue: negative; and red: positive)]. Three black “X”s indicate
that all three patients relapsed or had distant metastases during the observation period (case nos. 16, 59, and 62; Table S5)
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pathohistological score (Fig. 4b and Table S5). These data
might suggest that higher gene scores are associated with
poorer outcomes, regardless of pathohistological features;
however, additional cases must be examined to confirm our
hypothesis. Additionally, we detected OCT4 and SPP1 tran-
scripts at high frequencies in tumours with invasive regions
(gene score: ≥2.0; 15/17) (Fig. 4b and Table S5). Fig. 4c and
d show a significant correlation between OCT4A and
SPP1C expression in LUAD, according to Fisher’s exact
test. Interestingly, no tumours were OCT4A (−)/SPP1C (+),
suggesting that OCT4A might directly or indirectly up-
regulate SPP1C expression, which is consistent with the
data shown in Fig. 3h. Conversely, it is possible that OCT4A
(−)/SPP1C (−) status might predict good clinical outcomes
(Fig. 4d; n = 13). We proffer that these data suggest that tu-
mours expressing OCT4A and SPP1C might have different
cells of origin and display different pathological phenotypes
than OCT4A (−)/SPP1C (−) tumours.
Discussion
This represents the first study reporting conclusive evi-
dence of OCT4-transcript variants in healthy and cancer-
ous human tissues. Remarkably, we readily detected
OCT4A and OCT4B variants in some adult human som-
atic tissues, as well as in the gonads (Fig. 1). In contrast,
none of the Oct4 transcripts was detected in any of the ex-
amined tissues except the gonads from 4-month-old mice
(Fig. S1). We believe that these unexpected results will be
of value to oncology researchers and those investigating
stem cell biology. Most researchers routinely regard the
mouse as a suitable model for humans, and thus, results
obtained using mice are frequently applied to humans
without adequate consideration. Our data (Fig. 1) should
rekindle interest in the physiological and/or pathological
functions of OCT4-expressing cells in adulthood.
Until now, the somatic function of OCT4 remained un-
clear. We previously reported that OCT4A and B164
(OCT4C) isoforms might be the major products translated
from OCT4A and OCT4Bv mRNAs [16]. It was predicted
that the OCT4C protein isoform lacking the N-terminal
portion of OCT4A would not function as a transcription
factor (OCT4A) despite its ability to transform fibroblasts
in vitro, similar to OCT4A [16]. The different expression
patterns of OCT4A and OCT4Bv (Fig. 1a) and the possible
functional heterogeneity of OCT4 isoforms suggest that
variant-specific detection is important to elucidate the
function of human OCT4 in adult somatic tissues.
It remains unclear which cells in adult human somatic
tissues express OCT4A. No OCT4A-transcripts were de-
tected in bone marrow, MSC-AC, or MCS-BM (Fig. 1a),
suggesting that OCT4A-expressing somatic cells are not
hematopoietic or mesenchymal stem cells. Moreover,
OCT4A expression in human somatic tissues appeared
lower than that of PA-1, undifferentiated ovarian
teratocarcinoma cells, although levels in the lung tissue
were higher than the testis (Fig. 1d). If OCT4A-positive
somatic cells are scarce, it is likely that those expressing
OCT4A do so at significantly higher levels in certain
somatic tissues. These may be TICs or CSCs, and like
those in germ-cell tumours [6, 10], they may give rise to
certain cancers in human somatic tissues. To character-
ise the physiological and pathological roles of OCT4 in
human somatic cells, we could use, after appropriate
genetic modification, animal model other than mice as a
new model for humans.
In our previous and current analyses, we identified
subpopulations of OCT4-positive cells in the lung and
endometrial adenocarcinoma cell lines [16] that pro-
moted cell migration and invasion (Fig. 2e and Fig. 3g).
High expression levels of OCT4A and OCT4Bv, suggest-
ing that OCT4-positive cells are relatively common
among cancer cell lines and tumours, were closely re-
lated to SPP1 expression, and ablation of OCT4-positive
cells significantly decreased SPP1C-expression levels,
suggesting that OCT4A might directly or indirectly up-
regulate SPP1C expression in a subpopulation of cancer
cells. Additionally, we confirmed a significant correlation
between OCT4A and SPP1C expression in primary
LUAD tumours (Fig. 4c). Numerous studies suggest the
importance of SPP1-transcript variant expression in can-
cer progression and prognosis [42, 43]. The results of
the present study suggest that cancer cells positive for
the OCT4A/SPP1C axis might promote the aggressive-
ness of a variety of cancers.
Lung cancer is a major global health threat associated
with high disease-associated mortality rates [31]. The
overall prognosis for patients with lung cancer is poor,
and even for patients with early-stage disease, the postoper-
ative recurrence rate is high relative to other cancers. The
present study strongly suggests that co-expression of
OCT4A and SPP1C transcript variants may represent a
prognostic marker and therapeutic target for stage I LUAD,
and that their products may play a significant role in LUAD
development and progression. Limitations of our study in-
clude the small number of patients enrolled and the short
follow-up period. For further validation, larger-scale studies
over longer timelines must be performed. A more conveni-
ent and quantitative method for the detection of OCT4A-
and SPP1C-transcript variants might also be required. We
suggest that the variant-specific transcripts analysis can be
used more effectively than protein analysis for clinical appli-
cations, because the specificity of the OCT4A antibody re-
mains an unsolved problem. Moreover, the molecular
mechanisms responsible for the correlation between OCT4
and SPP1 in cancer cells was not elucidated; therefore, fu-
ture work should focus on investigating the roles of
OCT4A and SPP1C in tumour cell migration, as well as in
other biological activities.
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Conclusion
We demonstrated the significance of OCT4A- and
SPP1C-transcript variants in human carcinoma cell lines
and clinical LUAD tumour tissues. Notably, our ap-
proach for identifying full-length splice variants high-
lights a “blind spot” in previous large-scale analyses. Our
findings provide new insights into the basis of cell plasti-
city in normal and tumour tissues, which are essential
for the design of more efficient therapies that selectively
target CSCs/TICs [1, 2, 44]. The results of past studies
must be reassessed, and expression data for OCT4A-
and SPP1C-transcript variants should be collected using
both bioinformatics analysis and the reliable methods
described in this study. Our data suggest OCT4A as a
potential marker for CSCs/TICs, at least in certain hu-
man epithelial tumours. Moreover, we hypothesise that
up-regulated expression of OCT4A and SPP1C in cancer
cells, especially during the early stages of malignant
transformation, might indicate a propensity toward in-
creased migration, aggressiveness, and progression of
somatic cell tumours. We hope our findings help im-
prove the accurate diagnosis and prediction of early-
stage LUAD in a new era of personalised medicine and
provide a new approach for targeting tumour cell motil-
ity to prevent metastasis.
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